Centralized Sequences |
To reduce the genetic distance between immunogens and primary isolates to elicit a more cross reactive response |
Group M Consensus |
Increased Breadth of NAb Response |
[37, 38] |
Subtype B Consensus |
Increased NAb Potency Over Wild type Sequences |
[41] |
Subtype C Consensus |
No Appreciable Increase Nab Response |
[39] |
Ancestral B |
No Appreciable Increase Nab Response |
[40] |
Ancestral C |
No Appreciable Increase Nab Response |
[39] |
Variable Loop Deletions |
To make functionally important domains more accessible |
V1/V2, V3, & V4 Deletions |
No Appreciable Increase Nab Response |
[48, 52, 53] |
V2 Deletions |
Increased potency and small increases in breadth of NAb Response |
[49, 51, 52, 124] |
Glycosylation Mutants |
To shield irrelevant domains or expose important domains |
Hyperglycosylation |
Elimination of unwanted Ab specificities No improvement on overall NAb |
[61, 62] |
Targeted deletion |
Increased breadth and potency of NAb response is some isolates, no effect in others |
[63–66] |
Envelope Trimers |
To better mimic the natural state of functional trimer |
Eliminate Env cleavage site |
Study and Isolate Dependent |
[67, 68] |
Stabilized intermolecular interactions |
Inconsistent increases in potency of NAb titers to homologous isolates |
|
Env trimerized with heterologous motifs |
Increased potency of NAb Response |
[69, 70, 72] |
Epitope Grafting |
To make a neutralizable epitope more immunogenic when presented in a different context |
MPER Grafts |
No increases in NAbs with specificity for graft |
[76, 77] |